MPMaría Ángeles Puche-Larrubia

María Ángeles Puche-Larrubia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Ángeles Puche-Larrubia has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in long-term functional deterioration and permanent disability in spondyloarthritis: a 17-year follow-up from the REGISPON-3 study

    by Diana Maria Margareta Moldovan, Lourdes Ladehesa-Pineda, María Ángeles Puche-Larrubia, María Carmen Ábalos-Aguilera, Desirée Ruiz-Vilchez, Raquel Ena Granados, Carlos M Collantes-Sánchez, Alejandro Escudero-Contreras, REGISPON-3 Study Group, Eduardo Collantes-Estévez, et al.

    Objective: The primary objective was to assess sex differences in long-term functional deterioration and permanent work disability in spondyloarthritis (SpA), and the secondary aim to evaluate whether systemic inflammation mediates the association between biologic disease-modifying antirheumatic drugs (bDMARDs) exposure and functional change in a sex-dependent manner. Methods: A longitudinal observational study was conducted in 411 patients with SpA from the Spanish REGISPONSER registry (baseline 2004–2007), who were reassessed 17 years later in REGISPON-3 (2021–2024). Outcomes were Bath Ankylosing Spondylitis Functional Index (BASFI) at follow-up, ΔBASFI and permanent work disability. Sex-stratified logistic and multivariable linear regression models were used. Moderated mediation analysis evaluated C reactive protein (CRP) as a mediator of the association between bDMARD exposure and ΔBASFI, with sex as a moderator. Results: A total of 271 male patients with SpA (65.9%) and 140 female patients with SpA (34.1%) were included. At follow-up, female patients showed significantly worse functional status and greater functional deterioration (ΔBASFI 1.47±2.81 vs 0.38±2.57, p<0.001), whereas permanent disability rates were similar (27.1% vs 32.1%, p=0.31). Higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Radiology Index (BASRI)-total were independently associated with disability in both sexes. Baseline BASFI and BASDAI predicted ΔBASFI in both sexes; additional predictors in male patients included BASRI-total and occiput-to-wall distance, whereas BASRI-column was relevant in female patients. The indirect effect of bDMARD exposure on ΔBASFI through CRP was significant in male patients but not in female patients with a significant sex interaction. Conclusion: Female patients experienced greater long-term functional deterioration despite similar work disability rates at follow-up. The relationship between systemic inflammation and long-term functional outcomes may differ by sex.

  • Open Access

    Transcriptomic and proteomic analysis stratifies patients with axial spondyloarthritis based on disease activity, structural damage and radiographic progression

    by Laura Cuesta-López, Iván Arias-De la Rosa, Carlos Pérez-Sánchez, Ariana Barbera-Betancour, Miriam Ruiz-Ponce, Antonio Manuel Barranco, Pedro Ortiz-Buitrago, Lourdes Ladehesa-Pineda, María Ángeles Puche-Larrubia, Jesus Eduardo Martín-Salazar, et al.

    Objectives: To identify clusters of highly correlated genes enriched in biological functions and specific molecular pathways involved in the pathogenesis of radiographic damage in axial spondyloarthritis (axSpA) and to discover molecular biomarkers of radiographic progression and disease severity. Methods: A total of 144 patients with axSpA were included. First, RNA from peripheral blood mononuclear cells was sequenced in a cohort of 24 patients with axSpA. Hub genes were measured in a n=60 validation cohort through microfluidic PCR. A 5-year follow-up enabled the classification of the patients into fast/moderate or slow progressors. Machine learning approaches were applied to identify a predictive biomarker of progression by integrating gene expression data with clinical variables. An independent cohort of 60 patients with axSpA, with spine radiographs taken 5 years prior, underwent serum proteomic analysis using a Proximity Extension Assay. Results: Unsupervised clustering analysis using transcriptomics revealed two distinct groups of patients with axSpA, differentiated by their clinical profiles. Weight gene correlation network analysis identified six gene modules differentially expressed between the two clusters. Patients in cluster 2 exhibited higher disease activity, greater functional impairment and more structural damage. Molecular alterations linked to structural damage revealed a specific circulating inflammatory proteome profile associated with disease severity. A predictive model composed of two genes and basal total modified Stoke Ankylosing Spondylitis Spinal Score emerged as a key biomarker for identifying moderate-to-fast radiographic progression. Conclusions: This study identified molecular pathways involved in radiographic damage and discovered potential proteomic biomarkers of disease severity and transcriptomic predictors of radiographic progression in axSpA.


  • Open Access

    Uveitis in Longstanding Axial Spondyloarthritis and Its Association with Biologic Therapy Initiation: Data from the REGISPON-3 Cohort

    by Ana María Sánchez-León, María Lourdes Ladehesa-Pineda, María Ángeles Puche-Larrubia, María Carmen Ábalos-Aguilera, Desirée Ruiz-Vilchez, Alejandro Escudero-Contreras, Eduardo Collantes-Estévez, Carlos M. Collantes-Sánchez, Clementina López-Medina, REGISPON-3 Study Group

    Objectives: To assess the incidence rate of anterior acute uveitis (AAU) in patients with longstanding axial spondyloarthritis (axSpA); to evaluate demographic and clinical characteristics associated with AAU development; and to determine the influence of AAU on bDMARD initiation and retention in this population. Methods: This two-timepoint cohort study analysed data from patients enrolled in the Spanish SpA registry REGISPONSER (2004–2007), who were re-evaluated 17 years later in the REGISPON-3 follow-up study (2021–2023). Information on the date of first AAU episode and bDMARD initiation was collected. Kaplan–Meier and Cox proportional hazards models were used to assess AAU incidence, predictors, and its association with time to bDMARD initiation and treatment retention. Results: A total of 299 patients with longstanding axSpA were included, of whom 33.4% experienced at least one episode of AAU, corresponding to an incidence rate of 1.15 per 100 person-years. The cumulative probability of a first episode of AAU increased with disease duration. The relative risk for developing a second episode after the first, compared to the overall risk of any episode in the total population, was 1.85 (95% CI: 1.34–2.57). In multivariable cox analysis, female sex and baseline enthesitis were independently associated with a higher risk of AAU. AAU did not significantly affect the likelihood of subsequent bDMARD initiation, with similar cumulative treatment probabilities in patients with and without AAU. Among treated patients, adalimumab was more frequently prescribed in those with a history of AAU. bDMARD retention rates at two and five years were comparable regardless of AAU status, suggesting that AAU was not associated with long-term treatment persistence. Conclusions: In patients with longstanding axSpA, the incidence of AAU increased steadily over time. However, the presence of AAU did not significantly influence bDMARD initiation or long-term retention in routine clinical practice.

  • Open Access

    Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study

    by María Ángeles Puche-Larrubia, Lourdes Ladehesa-Pineda, María Carmen Ábalos-Aguilera, Desirée Ruiz-Vílchez, Laura Berbel-Arcobé, Xavier Juanola-Roura, Marta Arévalo-Salaet, Mireia Moreno, Raquel Almodóvar-González, Cristina Pijoan-Moratalla, et al.

    Objectives: To evaluate disease evolution, diagnostic transitions, time to biologic treatment initiation and mortality in patients with spondyloarthritis (SpA) after 17 years from the original Spanish Registry of Spondyloarthritis (REGISPONSER). Methods: Spondyloarthritis Registry 3 (REGISPON-3) is a two-timepoint longitudinal study with patients fulfilling the European Spondyloarthropathy Study Group criteria participating in the REGISPONSER study and re-evaluated after 17 years. Clinical, laboratory, radiological and treatment data were collected and compared with baseline. Diagnostic changes according to the rheumatologist’s judgement and their associated factors were analysed using multivariable logistic regression. Time to initiation of biologic therapy was evaluated using Kaplan-Meier survival analysis. Results: A total of 536 patients from the REGISPONSER study conducted in 2004 were contacted in 2021 for the REGISPON-3 visit. Of these, 411 were physically re-evaluated, while 125 were confirmed deceased. Among the 411 patients, 31.6% experienced a change in diagnosis in the REGISPON-3 visit, mainly from undifferentiated SpA to axial SpA or psoriatic arthritis. In multivariable analysis, dactylitis, younger age and lower Bath Ankylosing Spondylitis Radiology Index scores were associated with diagnostic change. The use of biologic disease-modifying antirheumatic drugs (bDMARDs) increased from 13.1% to 52.1%. However, the median time to first bDMARD from symptom onset was 32 years (95% CI 30 to 35) and 28 years from diagnosis (95% CI 26 to 32). Among the 125 patients who died, the leading causes were infections (21.6%), cardiovascular (CV) events (20.0%) and cancer (19.2%). Conclusions: This long-term reassessment reveals significant diagnostic changes in SpA and a mortality burden mainly attributed to infections and CV diseases.


  • Open Access

    A Twist in the Diagnosis: Chronic Arthropathy Without Inflammation

    by María Á. Puche‐Larrubia, Inmaculada C. Aranda‐Valera, Alejandro Escudero‐Contreras, Rosa Roldán‐Molina

  • Open Access

    From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis

    by Iván Arias-De la Rosa, Jesús Eduardo Martín-Salazar, Laura Cuesta-López, Clementina López-Medina C, Alejandro Escudero-Contreras, Eduardo Collantes-Estévez, Nuria Barbarroja, María Ángeles Puche-Larrubia

    Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by a complex interplay of molecular factors. Despite advances in understanding its pathophysiology, diagnostic delays and the absence of personalized treatment strategies remain significant challenges. This review provides a comprehensive analysis of imaging techniques and molecular approaches to improve disease characterization. Advanced imaging methods, including magnetic resonance imaging, positron emission tomography, and artificial intelligence (AI)-driven models, have enhanced diagnostic accuracy, reduced variability in interpretation, and facilitated early disease detection. In parallel, omics technologies have provided valuable insights into disease pathogenesis. Genomic studies have identified susceptibility loci beyond human leukocyte antigen B27, implicating key immune pathways such as interleukin-23/interleukin-17 signaling. Epigenomic modifications, particularly DNA methylation, play a key role in regulating gene expression in immune cells, especially within genetically predisposed loci. Transcriptomic studies have uncovered dysregulated immune pathways and revealed novel cellular players in disease pathogenesis, including CD99 + neutrophils, natural killer cells, and microRNAs—important post-transcriptional regulators that have shown high diagnostic accuracy when assessed in peripheral blood mononuclear cells. Proteomic analyses have further contributed by identifying potential biomarkers and therapeutic targets in blood using advanced technologies, highlighting molecules such as tumor necrosis factor, FK506-binding protein-like (FKBPL), mitogen-activated protein kinase 14 (MAPK14), interleukin 7 receptor, and interleukin-23 receptor, among others. Future research should focus on combining multi-omics data with AI-driven approaches to improve biomarker discovery, optimize patient classification, and guide personalized treatments. Bridging the gap between molecular insights and clinical applications will enable precision medicine strategies, improving early diagnosis and therapeutic outcomes in axSpA.


  • Open Access

    Molecular insights into the relationship between sustained CRP elevation and endothelial dysfunction in axial spondyloarthritis

    by Laura Cuesta-López, Iván Arias-De la Rosa, Jesús Eduardo Martín-Salazar, Antonio Manuel Barranco, Lourdes Ladehesa-Pineda, Miriam Ruiz-Ponce, María Ángeles Puche Larrubia, Carlos Pérez-Sánchez, Pedro Seguí, Rafaela Ortega, et al.

    Objectives: To investigate the impact of sustained C reactive protein (CRP) elevation on cardiovascular (CV) risk factors, particularly endothelial dysfunction and atherosclerosis, in axial spondyloarthritis (axSpA) patients and to explore the underlying molecular mechanisms. Methods: 245 axSpA patients were enrolled. Carotid intima-media thickness (CIMT) and microvascular endothelial function (post-ischaemic reactive hyperaemia) were measured. Retrospective CRP measurements from the past 5 years classified patients as having sustained high CRP if >50% of readings were elevated. Serum levels of 184 inflammation and CV disease-related proteins were analysed using a proximity extension assay, and in vitro studies were conducted in human umbilical vein endothelial cells. Results: 40% of axSpA patients had sustained CRP elevation, showing increased metabolic comorbidities, higher prevalence of atherosclerotic plaques and worse microvascular endothelial function compared with those with intermittent CRP elevations. Proteomic analysis identified 10 altered proteins, with interleukin 6 (IL-6) and CUB domain-containing protein 1 (CDCP-1) linked to endothelial dysfunction, higher CIMT and metabolic disturbances. Paraoxonase 3 (PON-3), the only downregulated protein, showed anti-inflammatory, antioxidant and antiatherogenic properties, restoring endothelial function in vitro. CDCP-1 was associated with atherosclerotic plaques and promoted endothelial adhesion, oxidative stress and inflammation in vitro. Anti-TNF-α therapy reduced inflammatory markers, complement components and the atherogenic index, while increasing high density lipoprotein, apolipoprotein A and PON-3 levels and decreasing IL-6 and CDCP-1 levels. Conclusions: Sustained CRP elevation in axSpA is strongly linked to increased CV risk, endothelial dysfunction and atherosclerosis. IL-6, CDCP-1 and PON-3 emerge as key mediators connecting inflammation to CV risk. Anti-tumour necrosis factor-α therapy improved the metabolic and inflammatory profile and modulated IL-6, CDCP-1 and PON-3 levels, supporting its role in managing CV risks in axSpA.


  • Open Access

    Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice

    by Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, Maria Luz García-Vivar, Joaquin Maria Belzunegui Otano, Beatriz Joven-Ibáñez, Cristina Vergara-Dangond, Marina Pavía-Pascual, Irati Urionaguena-Onaindia, Lucia Vega Alvarez, M. Ángeles Puche Larrubia, et al.

    Upadacitinib has demonstrated efficacy in psoriatic arthritis in clinical trials, but its real-world performance in difficult-to-treat PsA remains underexplored. This observational, multicenter, open-label study evaluated the efficacy and safety of upadacitinib in 134 patients with psoriatic arthritis (97 women, mean age 51.8 ± 11.2 years, mean disease duration 9.94 ± 7.72 years) who showed inadequate response to advanced therapies. Most patients (74.6%) had received at least two biological/targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action. Upadacitinib was initiated at 15 mg daily, and within one month, significant improvements were observed: DAS28-ESR decreased from 4.7 to 3.77 (p < 0.001), DAPSA from 25 to 17 (p < 0.001), and CRP from 2.90 to 1.50 mg/L (p = 0.001). These reductions persisted throughout the study. Prednisone dosage decreased significantly (p = 0.049). Adverse events led to upadacitinib discontinuation in 8.2% of patients, but no serious adverse events were reported. Compared to the SELECT-PsA 2 trial, our cohort had a higher proportion of females and greater prior exposure to biologic agents but showed comparable efficacy and safety outcomes. These findings suggest that upadacitinib is a rapid, effective, and relatively safe therapeutic option for difficult-to-treat psoriatic arthritis under real-world conditions, supporting its use despite differing patient characteristics from clinical trial populations.


  • Open Access

    Association Between Diagnostic Delay and Short-Term Outcomes in Patients with Radiographic Axial Spondyloarthritis: Results from the Regisponser-AS Registry

    by María Lourdes Ladehesa-Pineda, Desirée Ruiz-Vilchez, Antonio Manuel Barranco, María Ángeles Puche-Larrubia, Pilar Font-Ugalde, Raquel Ena María Granados, Jordi Gratacós-Mastmijà, Xavier Juanola, Alejandro Escudero-Contreras, Eduardo Collantes-Estévez, et al.

    Objectives: To evaluate whether the diagnostic delay in patients with radiographic axial spondyloarthritis (r-axSpA) is associated with poorer short-term outcomes after two years of follow-up. Methods: This was an observational, longitudinal, and prospective study including patients with r-axSpA from the national multicentre Spanish REGISPONSER-AS registry. Patients were divided into two groups according to the mean diagnostic delay (<5 years, ≥5 years). Binary logistic regression models adjusted for disease duration were constructed and used to evaluate the association between diagnostic delay and disease outcomes at two years. The retention rate for first-line treatment with anti-TNF across the groups was evaluated using a log-rank test. Results: A total of 565 patents were included. The mean diagnostic delay was 5.6 ± 6.2 years, with 325 patients experiencing a delay of <5 years and 240 patients experiencing a delay of ≥5 years. A diagnostic delay of ≥5 years was associated, after 2 years, with a higher prevalence of inflammatory bowel disease (IBD) (OR 2.01 (95%CI 1.06–3.83)), a lower prevalence of synovitis (OR 0.68 (95%CI 0.47–0.98)) and dactylitis (OR 0.24 (95%CI 0.11–0.55)), and worse disease activity after adjusting by disease duration. However, no impact was observed on quality of life, structural damage, or work disability, probably due to the short follow-up period. Finally, no differences between the groups were found with regard to the retention rate for first-line anti-TNF treatment. Conclusions: Diagnostic delay is associated with poorer short-term outcomes in terms of structural damage, dactylitis, and disability in patients with r-axSpA.


  • Open Access

    Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations

    by María Ángeles Puche-Larrubia, Lourdes Ladehesa-Pineda, Pilar Font-Ugalde, Rubén Burgos-Vargas, Percival Sampaio-Barros, José Maldonado-Cocco, Anabela Barcelos, Jordi Gratacós, Xavier Juanola, Alejandro Escudero-Contreras, et al.

    J Rheumatol 2025; doi:10.3899/jrheum.2024-1085The funding statement has been revised to the following: "This study was partially funded by the SER-GRESSER/JANSSEN grant, with no involvement from Janssen in its development."This correction applies only to the February 15 2025 First Release. The correct text appears in the print and online issues.